| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
It is a challenge to overcome the acquired resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI) in lung cancers harboring EGFR activating mutations. Epithelial-mesenchymal transition (EMT), which was one of the mechanisms of the acquired resistance to EGFR-TKI, was associated with miR-200, one of microRNAs. In addition, the expression of LIN28B gene was elevated in EGFR-TKI-resistant lung cancer cell lines. Cell proliferation was inhibited by the induction of miR-200c or the knockdown of LIN28B in EGFR-TKI-resistant lung cancer cell lines. Thus, it is considered that LIN28B was a potential therapeutic target for lung cancer with the acquired resistance to EGFR-TKI.
|
